Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

por Patnaik, A, Weiss, G J, Papadopoulos, K P, Hofmeister, C C, Tibes, R, Tolcher, A, Isaacs, R, Jac, J, Han, M, Payumo, F C, Cotreau, M M, Ramanathan, R K
Publicado 2014

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients

por Kortuem, K M, Braggio, E, Bruins, L, Barrio, S, Shi, C S, Zhu, Y X, Tibes, R, Viswanatha, D, Votruba, P, Ahmann, G, Fonseca, R, Jedlowski, P, Schlam, I, Kumar, S, Bergsagel, P L, Stewart, A K
Publicado 2016

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies

por Bogenberger, J M, Kornblau, S M, Pierceall, W E, Lena, R, Chow, D, Shi, C-X, Mantei, J, Ahmann, G, Gonzales, I M, Choudhary, A, Valdez, R, Camoriano, J, Fauble, V, Tiedemann, R E, Qiu, Y H, Coombes, K R, Cardone, M, Braggio, E, Yin, H, Azorsa, D O, Mesa, R A, Stewart, A K, Tibes, R
Publicado 2014